• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

With an ovarian KRAS combo ready for review, Verastem’s CEO is poised for the transition

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 04, 2024 at 11:22: AM
via Verastem Oncology is now on the precipice of filing for an accelerated approval of a RAS pathway-based combo to treat low-grade serous ovarian cancer, and the transition follows a CEO turnover as Daniel Paterson, who has been with the company “almost since the beginning,” took the helm last year.

article source
 




Top Bottom
Back
Quote